USRM Chief Science Officer Featured on One Radio Network

SUNRISE, FL – January 15, 2019 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer has been featured on Patrick Timpone’s One Radio Network. Playback of the interview is available here.

Dr. Kristin Comella, who has been frequently published in the scientific literature on the use and application of autologous (a patient’s own) adipose-derived stem cells, will speak on her expertise in the autologous stem cell space. Americans’ interest in stem cell therapy continues to grow, demand for Dr. Comella to present on the topic continues to increase.

“The interest surrounding the application of stem cell therapy as an alternative to chronic drug use is on the rise and is driving the advancement of regenerative medicine,” said Dr. Comella.  “We continue to see the positioning of stem cell therapy as an emergent catalyst that will impact the standard of care for our nation. In the coming years we will see more and more demand for information and education, as patients with chronic pain continue to learn more and more about their options for regenerating damaged tissue.”

Currently, Americans have the option to either utilize their own healing stem cells harvested from fat, bone marrow or to use tissue-based products like those manufactured from birth tissue or cord blood.

In the past twelve months alone, Dr. Comella has published several articles regarding the benefits of autologous stem cell therapy for chronic conditions, including decubitus ulcers (perpetual sores common in spinal injury patients and the elderly); meniscal tears, and psoriasis.  Chronic conditions can cause chronic pain — the source of a national opioid epidemic which The New York Times reports is the leading cause of death for Americans under the age of 50.

Autologous stem cell therapy involves taking a small sample of a patient’s fat and separating the stem cells from the fat or adipose tissue. Because stem cells from fat are 500 times more plentiful than stem cells harvested from bone marrow (and much less invasive to retrieve), the protocol has begun to attract more and more patients in the United States, even though the treatment has been available abroad and offshore for many years.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at